Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ11618MR)

This product GTTS-WQ11618MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 1
Species	Mus musculus; Humanized
RefSeq	NM_000733.4; NM_001267713.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	916; 3563
UniProt ID	P07766; P26951

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11618MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6862MR	IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	DX-2930
GTTS-WQ5681MR	IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CDX-011 (DOX)
GTTS-WQ11350MR	IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	MEDI-551
GTTS-WQ3240MR	IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ARGX-113
GTTS-WQ8194MR	IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	HL161
GTTS-WQ12536MR	IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	NPVPDR001
GTTS-WQ13610MR	IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	R1450
GTTS-WQ8642MR	IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	HuMax-AXL-ADC

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST